# Anders Hove

> Anders Hove is a Series C investor at Acorn Bioventures backing Health Care and Biotechnology. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Acorn Bioventures](https://shizune.co/investors/profile/acorn-bioventures)
- Location: New York, United States
- Total investments: 15
- Last investment: Jan 2009
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/pub/anders-hove/8a/387/732

Anders Hove is a Series C investor at Acorn Bioventures in New York focused on Health Care and Biotechnology. Anders Hove is the Partner and Founder at acorn Bioventures. Attended INSEAD.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 53% |
| Biotechnology | 6 | 40% |
| Medical | 4 | 27% |
| Therapeutics | 3 | 20% |
| Pharmaceutical | 3 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 4 | 27% |
| Series E | 2 | 13% |
| Funding Round | 2 | 13% |
| Series B | 1 | 7% |
| Series D | 1 | 7% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Intuity Medical | Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution formillions of patients who need to regularly test their blood glucose.The company was founded in 2002 and is headquartered in Fremont, California. | $40M |  | Nov 10, 2016 |  |
| Edge Therapeutics | Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patientoutcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain.It was founded in 2009 and is headquartered in Berkeley Heights, New Jersey. | $56M | Series C | Apr 09, 2015 |  |
| Mevion Medical Systems | Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $200M | Private Equity | Aug 04, 2014 |  |
| Coherus Biosciences | Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, andclinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. | $54.7M | Series C | May 19, 2014 |  |
| Intuity Medical | Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution formillions of patients who need to regularly test their blood glucose.The company was founded in 2002 and is headquartered in Fremont, California. | $5.5M |  | Jan 30, 2014 |  |
| Mevion Medical Systems | Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $55M | Private Equity | Jun 25, 2013 |  |
| Intuity Medical | Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution formillions of patients who need to regularly test their blood glucose.The company was founded in 2002 and is headquartered in Fremont, California. | $12M |  | Aug 09, 2012 |  |
| Mevion Medical Systems | Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $45M |  | Jan 24, 2012 |  |
| Intuity Medical | Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution formillions of patients who need to regularly test their blood glucose.The company was founded in 2002 and is headquartered in Fremont, California. | $12M | Series D | Aug 01, 2011 |  |
| Intuity Medical | Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution formillions of patients who need to regularly test their blood glucose.The company was founded in 2002 and is headquartered in Fremont, California. | $64M | Series D | Jan 05, 2010 |  |

10 of 15 investments shown.

## Co-investors
- [CHL Medical Partners](https://shizune.co/investors/profile/chl-medical-partners) — VC Fund, 3 deals together
- [ProQuest Investments](https://shizune.co/investors/profile/proquest-investments) — VC Fund, 3 deals together
- [U.S. Venture Partners](https://shizune.co/investors/profile/us-venture-partners) — VC Fund, 3 deals together
- [Aberdare Ventures](https://shizune.co/investors/profile/aberdare-ventures) — VC Fund, 2 deals together
- [Accuitive Medical Ventures](https://shizune.co/investors/profile/accuitive-medical-ventures) — VC Fund, 2 deals together
- [Care Capital](https://shizune.co/investors/profile/care-capital) — VC Fund, 2 deals together

## About Acorn Bioventures

VC Fund · New York, United States

Our invest in and partner with private and small capitalization biotech, specialty pharma and medical device companies.

2 contacts available at Acorn Bioventures.

| Name | Title | Profile |
| --- | --- | --- |
| Anders Hove | Partner & Founder | https://shizune.co/investors/profile/anders-hove |
| Isaac Manke | Partner | https://shizune.co/investors/profile/isaac-manke |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Anders Hove invest in?

Anders Hove invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series E stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Anders Hove last invest?

The most recent investment recorded for Anders Hove closed in Jan 2009. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co